In yesterday’s Wall Street session, Eli Lilly and Company (NYSE:LLY) shares traded at $468.98, up 0.97% from the previous session.
As of this writing, 27 analysts cover Eli Lilly and Company (NYSE:LLY). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $550.00 and a low of $300.00, we find $474.50. Given the previous closing price of $464.49, this indicates a potential upside of 2.16 percent. LLY stock price is now 9.05% away from the 50-day moving average and 28.23% away from the 200-day moving average. The market capitalization of the company currently stands at $439.64B.
There are 5 analysts who have given it a hold rating, whereas 18 have given it a buy rating. Brokers who have rated the stock have averaged $452.32 as their price target over the next twelve months.
With the price target enhanced from $447 to $498, UBS maintained Buy rating for Eli Lilly and Company (NYSE: LLY).
In other news, LILLY ENDOWMENT INC, 10% Owner sold 44,115 shares of the company’s stock on Jun 29. The stock was sold for $20,517,137 at an average price of $465.08. Upon completion of the transaction, the 10% Owner now directly owns 101,192,935 shares in the company, valued at $47.46 billion. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 28, 10% Owner LILLY ENDOWMENT INC sold 11,760 shares of the business’s stock. A total of $5,473,168 was realized by selling the stock at an average price of $465.41. This leaves the insider owning 101,237,050 shares of the company worth $47.48 billion. Insiders disposed of 2,790,764 shares of company stock worth roughly $1.31 billion over the past 1 year. A total of 10.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LLY stock. A new stake in Eli Lilly and Company shares was purchased by OFI INVEST ASSET MANAGEMENT during the first quarter worth $24,872,533,000. EDGEWOOD MANAGEMENT LLC invested $994,889,000 in shares of LLY during the first quarter. In the first quarter, ORBIMED ADVISORS LLC acquired a new stake in Eli Lilly and Company valued at approximately $87,230,000. SUMMIT WEALTH GROUP, LLC acquired a new stake in LLY for approximately $65,067,000. SOFINNOVA INVESTMENTS, INC. purchased a new stake in LLY valued at around $64,297,000 in the second quarter. In total, there are 3,352 active investors with 84.80% ownership of the company’s stock.
Friday morning saw Eli Lilly and Company (NYSE: LLY) opened at $464.65. During the past 12 months, Eli Lilly and Company has had a low of $296.32 and a high of $468.53. As of last week, the company has a debt-to-equity ratio of 1.69, a current ratio of 1.30, and a quick ratio of 1.00. According to the stock market information, the enterprise value for the company is $456.14B, which is based on a 74.45 price-to-earnings ratio, a 3.03 price-to-earnings-growth ratio, and a beta of 0.37. The fifty day moving average price for LLY is $432.05 and a two-hundred day moving average price translates $366.54 for the stock.
The latest earnings results from Eli Lilly and Company (NYSE: LLY) was released for Mar, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.62, missing analysts’ expectations of $1.73 by -0.11. This compares to $2.10 EPS in the same period last year. The net profit margin was 20.50% and return on equity was 56.20% for LLY. The company reported revenue of $6.96 billion for the quarter, compared to $7.81 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -10.88 percent. For the current quarter, analysts expect LLY to generate $7.53B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 09/08/2023. Investors who held shares on 08/15/2023 were paid a $1.13 dividend. On an annualized basis, this represents a $4.52 dividend and a 0.96% percent yield. There was an ex-dividend date of 08/14/2023 for this dividend. In terms of dividend payout ratio, LLY is presently at 64.50%.
Eli Lilly and Company(LLY) Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
